La Puente, California Clinical Trials

A listing of La Puente, California clinical trials actively recruiting patient volunteers.

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Languages supported at study center
Age Group

Male only (5)
Any (49)

Phase 0 (1)
Phase 1 (13)
Phase 1/2 (1)
Phase 2 (8)
Phase 3 (9)
Unknown (22)

Interventional (35)
Observational (7)

City of Hope Medical Center (5)
Amgen (3)
Hoffmann-La Roche (3)
Sanofi (3)
Cairo University (2)
Genentech, Inc. (2)
Seagen Inc. (2)
AbbVie (1)
Arcus Biosciences, Inc. (1)
Astellas Pharma Global Development, Inc. (1)
CRISPR Therapeutics AG (1)
Delta University for Science and Technology (1)
Eli Lilly and Company (1)
Epizyme, Inc. (1)
Hacettepe University (1)
Hoag Memorial Hospital Presbyterian (1)
IVERIC bio, Inc. (1)
Kafrelsheikh University (1)
Mahidol University (1)
Merck Sharp & Dohme LLC (1)
National Cancer Institute (NCI) (1)
Papworth Hospital NHS Foundation Trust (1)
Poseida Therapeutics, Inc. (1)
Poznan University of Medical Sciences (1)
Queen's University (1)
Sage Therapeutics (1)
TrialX (1)
University of Bern (1)
University of Jordan (1)
University of Split, School of Medicine (1)
Vyriad, Inc. (1)
pfizer (1)

No (46)
Yes (8)

No (29)
Yes (25)

English (3)
Australian English (2)
Arabic (1)
Argentinian Spanish (1)
Armenian (1)
Azerbaijani (1)
Brazilian Portuguese (1)
British English (1)
Catalan (1)
Hindi (1)
Italian (1)
Norwegian Bokmål (1)
Spanish (1)
french (1)

Adult (18+) (53)
Pediatric (Under 18) (19)

I am/have/had

I am/have/hadnon-small cell lung cancer

I am/have/hadsystemic therapy

I am/have/hadMRI

I am/have/hadhepatitis

I am/have/hadcardiovascular disease

I am/have/hadplatelet transfusion

I am/have/hadcns involvement

I am/have/hadacute leukemia

I am/have/hadgilbert's syndrome

I am/have/hadpd-l1

I am/have/hadantibiotics

I am/have/hadchronic lymphocytic leukemia

I am/have/hadsolid tumour

I am/have/hadchromosome abnormality

I am/have/hadcns tumors

I am/have/hadplatelet count

I am/have/hadbone scan

I am/have/hadcancer treatment

I am/have/hadrefractory multiple myeloma

I am/have/hadneutrophil count

added new label for I am/have/had

I am looking for

I am looking forproteasome inhibitor

I am looking forgrowth factor

I am looking foranxiolytics

I am looking forimmune checkpoint inhibitor

I am looking forantibiotics

I am looking fornervous system

I am looking fordexamethasone

I am looking forpegfilgrastim

I am looking forhepatitis b

I am looking forabiraterone

I am looking forenfortumab vedotin

I am looking fordaratumumab

I am looking fornitrosoureas

I am looking forgonadotropin releasing hormone

I am looking foranticoagulants

I am looking forgranulocyte colony stimulating factor

I am looking forimmunomodulator

I am looking for131i-mibg

I am looking forgonadorelin

I am looking fordopamine transporter

added new label for I am looking for

Advanced Filters

Found 53 clinical trials

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 100s
Interventional Study
For Males
Family Medicine
Recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

prostatic neoplasms, castration-resistant

castration-resistant prostate cancer

measurable disease

cancer

taxane

The Oncology Institute of Hope & Innovation

(5.8 away) Contact site

0 views
16 Feb, 2024
+21 other locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D) Secondary Objectives: To characterize the safety profile of SAR442257 To characterize the …

cancer

cancer therapy

ejection fraction

recurrent disease

excisional biopsy

Investigational Site Number 8400001

(9.5 away) Contact site

0 views
04 Dec, 2020
+4 other locations

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …

autologous hematopoietic stem cell transplant

monoclonal protein

proteasome inhibitor

cell transplantation

monoclonal antibodies

Investigational Site Number 8400002

(9.5 away) Contact site

0 views
04 Dec, 2020
+7 other locations